R
Richard Wormald
Researcher at University College London
Publications - 17
Citations - 1073
Richard Wormald is an academic researcher from University College London. The author has contributed to research in topics: Randomized controlled trial & Ocular hypertension. The author has an hindex of 10, co-authored 17 publications receiving 748 citations. Previous affiliations of Richard Wormald include Moorfields Eye Hospital & University of London.
Papers
More filters
Journal ArticleDOI
Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial
David F. Garway-Heath,David P. Crabb,Catey Bunce,Gerassimos Lascaratos,Francesca Amalfitano,Nitin Anand,Augusto Azuara-Blanco,Rupert R A Bourne,David C Broadway,Ian A. Cunliffe,Jeremy P. Diamond,Scott G Fraser,Tuan A. Ho,Keith R Martin,Andrew McNaught,Anil Negi,Krishna Patel,Richard A. Russell,Richard A. Russell,Ameet Shah,Paul G. D. Spry,Katsuyoshi Suzuki,E.T. White,Richard Wormald,Wen Xing,Thierry Zeyen +25 more
TL;DR: This is the first randomised placebo-controlled trial to show preservation of the visual field with an intraocular-pressure-lowering drug in patients with open-angle glaucoma, and visual field preservation was significantly longer in the latanoprost group than in the placebo group.
Journal ArticleDOI
Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial
Gus Gazzard,Gus Gazzard,Evgenia Konstantakopoulou,Evgenia Konstantakopoulou,David F. Garway-Heath,David F. Garway-Heath,Anurag Garg,Anurag Garg,Victoria Vickerstaff,Rachael Hunter,Gareth Ambler,Catey Bunce,Catey Bunce,Richard Wormald,Richard Wormald,Richard Wormald,Neil Nathwani,Keith Barton,Keith Barton,Gary S. Rubin,Marta Buszewicz,Rupert R A Bourne,David C Broadway,Amanda Davis,Hari Jayaram,Yuzhen Jiang,Sheng Lim,Joanna Liput,Timothy Manners,Stephen Morris,Nicholas G. Strouthidis,Sarah L Wilson,Haogang Zhu +32 more
TL;DR: Over 36 months, from an ophthalmology cost perspective, there was a 97% probability of selective laser trabeculoplasty as first treatment being more cost-effective than eye drops first at a willingness to pay of £20 000 per quality-adjusted life-year gained.
Journal ArticleDOI
Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial. A multicentre, randomised controlled trial: design and methodology
Gus Gazzard,Gus Gazzard,Evgenia Konstantakopoulou,Evgenia Konstantakopoulou,Evgenia Konstantakopoulou,David F. Garway-Heath,David F. Garway-Heath,Keith Barton,Richard Wormald,Richard Wormald,Stephen Morris,Rachael Hunter,Gary S. Rubin,Marta Buszewicz,Gareth Ambler,Catey Bunce,Catey Bunce,Catey Bunce +17 more
TL;DR: The LiGHT Trial is a multicentre, pragmatic, randomised clinical trial that will provide valuable data on the relative HRQL, clinical effectiveness and cost-effectiveness of SLT and topical IOP-lowering medication.
Journal ArticleDOI
National survey of antimetabolite use in glaucoma surgery in the United Kingdom
TL;DR: In this paper, the authors assess the pattern of use of antimetabolites in trabeculectomy surgery by all consultant ophthalmologists in the United Kingdom.
Journal ArticleDOI
The effectiveness of schemes that refine referrals between primary and secondary care--the UK experience with glaucoma referrals: the Health Innovation & Education Cluster (HIEC) Glaucoma Pathways Project.
Gokulan Ratnarajan,Wendy Newsom,Wendy Newsom,Stephen A. Vernon,Cecilia Fenerty,Cecilia Fenerty,David B. Henson,David B. Henson,Fiona Spencer,Fiona Spencer,Yanfang Wang,Yanfang Wang,Robert Harper,Robert Harper,Andrew I McNaught,Lisa Collins,Mike Parker,John G Lawrenson,Robyn Hudson,Peng T. Khaw,Richard Wormald,David F. Garway-Heath,Rupert R A Bourne +22 more
TL;DR: OSIs can reduce FVDR of patients reviewed in secondary care; however, in terms of ‘patient safety’ this study also shows that overemphasis on IOP as a criterion for referral is having an adverse effect on both the non-OSIs and indeed the OSIs ability to detect glaucomatous optic nerve features.